Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-819 and Gemcitabine in Locally Advanced Pancreatic Adenocarcinoma
NCT01413087Phase 2Terminated
- Sponsor
- Anchiano Therapeutics Ltd.
- Start
- Sep 2011
- Primary completion
- Jan 2013
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 2
01
Overview
A Phase 2 trial of inodiftagene vixteplasmid in pancreatic adenocarcinoma (PDAC), sponsored by Anchiano Therapeutics Ltd.. Started Sep 2011; status: terminated.
02
Drugs
inodiftagene vixteplasmid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT01413087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01413087.